Atrial Fibrillation (AF) Clinical Trials in Boston, Massachusetts

5 studies are recruiting for atrial fibrillation (af) in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

   This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillat…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Beth Israel Lahey Health, Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts

   Locations

   81 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07175428 on ClinicalTrials.gov

2. Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

   Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single p…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   30 in total

   Run by

   Medtronic Cardiac Ablation Solutions

   See if you can join NCT07298473 on ClinicalTrials.gov

3. Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

   A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

   Stage

   Phase 3

   Ages

   65 and older

   Site

   Anthos Investigative Site 9918, Boston, Massachusetts

   Locations

   789 in total

   Run by

   Anthos Therapeutics, Inc.

   See if you can join NCT05712200 on ClinicalTrials.gov

4. Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

   The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF). Current guidelines recommend continued anticoagulation based on stroke risk scores, even post-ablation, potentially exposing patients to unnecessary …

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Brigham and Women Hospital, Boston, Massachusetts

   Locations

   12 in total

   Run by

   China National Center for Cardiovascular Diseases

   See if you can join NCT06615596 on ClinicalTrials.gov

5. Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

   PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure involving neuraxial anesthesia. The purpose of the PAUSE 2 study is t…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Woman's Hospital, Boston, Massachusetts

   Locations

   14 in total

   Run by

   McMaster University

   See if you can join NCT06957366 on ClinicalTrials.gov